- Home
- SPT vs AKBA Comparison
SPT vs AKBA Comparison
Compare SPT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- AKBA
- Stock Information
- Founded
- SPT 2010
- AKBA 2007
- Country
- SPT United States
- AKBA United States
- Employees
- SPT N/A
- AKBA N/A
- Industry
- SPT Computer Software: Prepackaged Software
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- SPT Technology
- AKBA Health Care
- Exchange
- SPT Nasdaq
- AKBA Nasdaq
- Market Cap
- SPT 1.1B
- AKBA 958.6M
- IPO Year
- SPT 2019
- AKBA 2014
- Fundamental
- Price
- SPT $18.89
- AKBA $3.51
- Analyst Decision
- SPT Buy
- AKBA Strong Buy
- Analyst Count
- SPT 13
- AKBA 5
- Target Price
- SPT $31.69
- AKBA $6.90
- AVG Volume (30 Days)
- SPT 547.0K
- AKBA 3.3M
- Earning Date
- SPT 08-06-2025
- AKBA 08-07-2025
- Dividend Yield
- SPT N/A
- AKBA N/A
- EPS Growth
- SPT N/A
- AKBA N/A
- EPS
- SPT N/A
- AKBA N/A
- Revenue
- SPT $418,413,000.00
- AKBA $184,909,000.00
- Revenue This Year
- SPT $12.33
- AKBA $26.88
- Revenue Next Year
- SPT $11.83
- AKBA $44.34
- P/E Ratio
- SPT N/A
- AKBA N/A
- Revenue Growth
- SPT 17.79
- AKBA N/A
- 52 Week Low
- SPT $18.32
- AKBA $1.07
- 52 Week High
- SPT $39.75
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- SPT 41.15
- AKBA 41.54
- Support Level
- SPT $18.56
- AKBA $3.77
- Resistance Level
- SPT $19.41
- AKBA $4.04
- Average True Range (ATR)
- SPT 0.66
- AKBA 0.16
- MACD
- SPT 0.04
- AKBA -0.07
- Stochastic Oscillator
- SPT 24.05
- AKBA 6.57
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.